Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Jing He

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-1954-2892; OpenAlex author ID A5078170323. Sources: OpenAlex.

Their work

Papers
16 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
91
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 3 papers · 2024: 5 papers · 2025: 5 papers · 2026: 2 papers

Papers 16

  1. Informing Decision-making for Transected Margin Reresection in Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer: An International Multicenter … Co-author DOI 10.1097/sla.0000000000006532↗
  2. Incidental Diagnosis of Pancreatic Cancer and Association with Improved Patient Outcomes: Assessing the Potential Clinical Use of Liquid Biopsy-Based Screening… Last author DOI 10.1097/xcs.0000000000001721↗
  3. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  4. Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5191↗
  5. Effect of travel distance on utilization of ancillary services among patients with pancreatic ductal adenocarcinoma: A single institution study. Co-author DOI 10.1007/s00520-025-09339-3↗
  6. Neoadjuvant Chemotherapy for Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006687↗
  7. Homologous recombination-DNA damage response defects increase TMB and neoantigen load, but not effector T cell density and clonal diversity in pancreatic cance… Co-author DOI 10.1186/s40164-025-00673-0↗
  8. An international multi-institutional validation of T1 sub-staging of intraductal papillary mucinous neoplasm-derived pancreatic cancer. Co-author DOI 10.1093/jnci/djae166↗
  9. Outcomes in intraductal papillary mucinous neoplasm-derived pancreatic cancer differ from PanIN-derived pancreatic cancer. Co-author DOI 10.1111/jgh.16686↗
  10. Consensus, debate, and prospective on pancreatic cancer treatments. Co-author DOI 10.1186/s13045-024-01613-x↗
  11. Evaluation of AJCC Nodal Staging for Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-024-16055-5↗
  12. Variation in outcomes and practice patterns among patients with localized pancreatic cancer: the impact of the pancreatic cancer multidisciplinary clinic. Co-author DOI 10.3389/fonc.2024.1427775↗
  13. Early Recurrence After Resection of Locally Advanced Pancreatic Cancer Following Induction Therapy: An International Multicenter Study. Co-author DOI 10.1097/sla.0000000000005666↗
  14. Persistent Circulating Tumor Cells at 1 Year After Oncologic Resection Predict Late Recurrence in Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005708↗
  15. A Delay in Adjuvant Therapy Is Associated With Worse Prognosis Only in Patients With Transitional Circulating Tumor Cells After Resection of Pancreatic Ductal … Co-author DOI 10.1097/sla.0000000000005710↗
  16. ASO Author Reflections: Do Distinct Patterns of Recurrence Impact the Prognosis of Patients With Resected Pancreatic Ductal Adenocarcinoma? Last author DOI 10.1245/s10434-018-6820-z↗

Closest collaborators

The 25 strongest of 91 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ammar A. Javed · 8 shared papers, 2023–2026 · strength 1.63
  2. Joseph R. Habib · 7 shared papers, 2023–2026 · strength 1.45
  3. Lois A. Daamen · 6 shared papers, 2023–2026 · strength 1.10
  4. Izaak Quintus Molenaar · 6 shared papers, 2023–2026 · strength 1.10
  5. Marc G. Besselink · 6 shared papers, 2023–2026 · strength 1.10
  6. Christopher L. Wolfgang · 5 shared papers, 2023–2026 · strength 1.08
  7. Christopher Lee Wolfgang · 6 shared papers, 2018–2026 · strength 1.06
  8. Ingmar Florin Rompen · 5 shared papers, 2024–2026 · strength 0.96
  9. Benedict Kinny‐Köster · 5 shared papers, 2023–2026 · strength 0.92
  10. Lei Zheng · 4 shared papers, 2023–2025 · strength 0.91
  11. Amol Kumar Narang · 3 shared papers, 2024–2025 · strength 0.80
  12. Martin Loos · 4 shared papers, 2024–2026 · strength 0.76
  13. Paul C. M. Andel · 4 shared papers, 2024–2026 · strength 0.76
  14. Greg D. Sacks · 4 shared papers, 2024–2026 · strength 0.76
  15. Hjalmar C. van Santvoort · 4 shared papers, 2023–2026 · strength 0.73
  16. Markus Wolfgang Büchler · 3 shared papers, 2024–2026 · strength 0.59
  17. Brady A. Campbell · 3 shared papers, 2024–2026 · strength 0.59
  18. Priya Pathak · 2 shared papers, 2024–2025 · strength 0.56
  19. Amy Hacker‐Prietz · 2 shared papers, 2024–2025 · strength 0.56
  20. Daniel Brock Hewitt · 3 shared papers, 2024–2025 · strength 0.52
  21. Vincent P. Groot · 3 shared papers, 2018–2023 · strength 0.43
  22. Adrian Theophil Billeter · 2 shared papers, 2025–2026 · strength 0.41
  23. Elliot K. Fishman · 1 shared paper, 2026 · strength 0.33
  24. Ralph H. Hruban · 1 shared paper, 2026 · strength 0.33
  25. Alina Hasanain · 2 shared papers, 2023 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.